



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer, PhD, MS, PMP
Cabinet Secretary

Cynthia Beane, MSW, LCSW
Commissioner

Effective January 1, 2026, West Virginia Medicaid and WVCHIP will allow high investment drug therapies to be carved out of the in-patient Diagnosis Related Group (DRG) rate and billed separately with a Healthcare Common Procedure Code System (HCPCS) code, except for Casgevy and Lyfgenia which must be billed through the Point of Sale (POS) system. All drugs on this list will require prior authorization.

Drugs currently carved out:

Abecma (idecabtagene vicleucel)
Aucatzyl (obecabtagene autoleucel)
Breyanzi (lisocabtagene maraleucel)
Carvykti (ciltacabtagene autoleucel)
Casgevy (exagamglogene autotemcel)
Elevidys (delandistrogene moxeparvovec-rokl)
Hemgenix (etranacogene dezaparvovec-drlb)
Kymriah (tisagenlecleucel)
Lenmeldy (atidarsagene autotemcel)
Lutathera (lutetium Lu 177 dotatate)
Luxturna (voretigene neparvovec-rzyl)
Lyfgenia (lovotibeglogene autotemcel)
Spinraza (nusinersen)
Roctavian (valoctocogene roxaparvovec-rvox)
Ryoncil (remestemcel-L-rknd)
Tecartus (brexucabtagene autoleucel)
Tecelra (afamitresgene autoleucel)
Yescarta (axicabtagene ciloleucel)
Zolgensma (onasemnogene abeparvovec-xioi)
Zynteglo (betibeglogene autotemcel)

Long-Acting Reversible Contraceptives (LARCs) may also be billed outside the DRG rate when provided immediately postpartum during the hospital stay. Additional information regarding inpatient LARC coverage can be found at <https://bms.wv.gov/media/40127>.

